Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Quarterly Earnings Results, Misses Expectations By $0.25 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the consensus estimate of ($1.71) by ($0.25), Briefing.com reports. Ultragenyx Pharmaceutical had a negative return on equity of 51.40% and a negative net margin of 470.18%. The business had revenue of $25.80 million for the quarter, compared to analyst estimates of $28.88 million. During the same period last year, the business posted ($1.74) EPS. Ultragenyx Pharmaceutical’s revenue was up 119.4% on a year-over-year basis.

NASDAQ:RARE traded up $1.40 during mid-day trading on Friday, reaching $38.90. 481,795 shares of the stock were exchanged, compared to its average volume of 546,206. The company has a 50 day simple moving average of $42.14 and a 200-day simple moving average of $54.60. The stock has a market capitalization of $2.30 billion, a P/E ratio of -5.26 and a beta of 2.15. The company has a quick ratio of 9.14, a current ratio of 9.32 and a debt-to-equity ratio of 0.04. Ultragenyx Pharmaceutical has a 1 year low of $36.73 and a 1 year high of $74.50.

A number of research analysts recently issued reports on RARE shares. Cowen restated a “buy” rating and set a $62.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. Leerink Swann restated a “positive” rating and set a $85.00 price target (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 4th. JPMorgan Chase & Co. restated a “buy” rating and set a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Morgan Stanley dropped their price target on Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $71.92.

In other news, CEO Emil D. Kakkis purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were purchased at an average price of $43.63 per share, for a total transaction of $218,150.00. Following the purchase, the chief executive officer now directly owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Story: What are gap-down stocks?

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.